Sharon Brangman

Nov 1, 2023 | agsjournals.onlinelibrary.wiley.com | Nathaniel Chin |Eric Widera |Sharon Brangman |Jason Karlawish

The US Food and Drug Administration (FDA) approval of monoclonal antibodies (MAB) targeting amyloid protein for treatment of Alzheimer's disease has ushered in a new era in Alzheimer's care. Disease-modifying therapies are now available to patients living with cognitive impairment and confirmed presence of brain beta-amyloid. Many geriatricians have voiced concerns and even outright disagreement with their approval and clinical use.1, 2 Many of these concerns are valid.

Jul 17, 2023 | jamanetwork.com | Eric Widera |Sharon Brangman |Nathaniel Chin

Ushering in a New Era of Alzheimer Disease Therapy Trial of Donanemab in Early Symptomatic Alzheimer Disease John R. Sims, MD; Jennifer A. Zimmer, MD; Cynthia D. Evans, PhD; Ming Lu, MD, MS, MPH; Paul Ardayfio, PhD; JonDavid Sparks, PhD; Alette M. Wessels, PhD; Sergey Shcherbinin, PhD; Hong Wang, PhD; Emel Serap Monkul Nery, MD; Emily C. Collins, PhD; Paul Solomon, PhD; Stephen Salloway, MD; Liana G.